Cargando…

Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients: Ready for Prime Time?

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Aras, Mandar A., Power, John R., Moslehi, Javid J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352214/ https://www.ncbi.nlm.nih.gov/pubmed/34396257 http://dx.doi.org/10.1016/j.jaccao.2020.08.001

Ejemplares similares

Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor‐associated cardiotoxicity
por: Liang, Lin, et al.
Publicado: (2023)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions
por: Moslehi, Javid, et al.
Publicado: (2022)

Cardiotoxicity from immune checkpoint inhibitors
por: Michel, Lars, et al.
Publicado: (2019)

The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
por: Nardi Agmon, Inbar, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors—Associated Cardiotoxicity
por: Li, Chenghui, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
por: Chen, Ru, et al.
Publicado: (2022)

Cardiotoxicity Associated with Immune Checkpoint Inhibitors
por: Minegishi, Shintaro, et al.
Publicado: (2023)

Biomarkers for Chronic Lung Allograft Dysfunction: Ready for Prime Time?
por: Verleden, Stijn E., et al.
Publicado: (2022)

Immune-checkpoint inhibitors: long-term implications of toxicity
por: Johnson, Douglas B., et al.
Publicado: (2022)

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Upadhrasta, Sireesha, et al.
Publicado: (2019)

Cardiotoxicity risk factors with immune checkpoint inhibitors
por: Brumberger, Zachary L., et al.
Publicado: (2022)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Cancer Biomarkers: Are We Ready for the Prime Time?
por: Mishra, Alok, et al.
Publicado: (2010)

Editorial: Recent Advances in Cardiotoxicity Testing
por: Mohamed, Tamer M. A., et al.
Publicado: (2021)

Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)

Plasma biomarkers for neurodegenerative disorders: ready for prime time?
por: Balogun, Wasiu G., et al.
Publicado: (2023)

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
por: Guo, Xiaoxiao, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance
por: Mascolo, Annamaria, et al.
Publicado: (2021)

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

HDAC Inhibition to Prime Immune Checkpoint Inhibitors
por: Borcoman, Edith, et al.
Publicado: (2021)

Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
por: Wright, Jordan J., et al.
Publicado: (2018)

Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies
por: Xu, Shirley, et al.
Publicado: (2021)

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
por: Ronen, Daniel, et al.
Publicado: (2022)

An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors
por: Esposito, Roberta, et al.
Publicado: (2021)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis
por: Liu, Maobai, et al.
Publicado: (2022)

REBOA: is it ready for prime time?
por: Doucet, Jay, et al.
Publicado: (2017)

A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors?
por: Moradi, Ali, et al.
Publicado: (2023)

Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting
por: Moey, Melissa Y.Y., et al.
Publicado: (2020)

Pediatric Post-TB Lung Disease: Ready for Prime Time?
por: Masekela, Refiloe, et al.
Publicado: (2023)

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
por: Johnson, Douglas B., et al.
Publicado: (2019)

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
por: She, Jianqing, et al.
Publicado: (2022)

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
por: Li, Yiqun, et al.
Publicado: (2022)

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
por: Toribio-García, Irene, et al.
Publicado: (2023)

Novel TGF-β inhibitors ready for prime time in onco-immunology
por: de Gramont, Armand, et al.
Publicado: (2016)

Multiplexed Immunohistochemistry for Molecular and Immune Profiling in Lung Cancer—Just About Ready for Prime-Time?
por: Hofman, Paul, et al.
Publicado: (2019)

Is pocket ultrasound ready for prime time?
por: Galen, Benjamin T
Publicado: (2012)

Radiotherapy for HCC: Ready for prime time?
por: Bang, Andrew, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ju0efgj51go8skr4v84iuvvpf7